Doctors Note Logo

Published on: 1/9/2026

What is nurtec used for?

Nurtec ODT (rimegepant) is an FDA-approved oral medication for adults with migraine. It has two uses: treating an acute migraine attack (with or without aura) and preventing episodic migraine when taken on a scheduled basis.

Key considerations before starting Nurtec include:

  • Who it's for: Adults 18+ with migraine; not studied in children.
  • Dosing: 75 mg orally disintegrating tablet; relief often begins within 1–2 hours.
  • Side effects: Nausea and, rarely, hypersensitivity reactions.
  • Liver and kidney limits: Avoid in severe hepatic impairment or end-stage renal disease.
  • Pregnancy and breastfeeding: Limited data—discuss risks with your clinician.
  • Drug interactions: Strong CYP3A4 inhibitors and inducers can affect blood levels.

Because migraine symptoms can overlap with other conditions—like tension headaches, cluster headaches, or more serious neurological issues—it's important to be sure you're treating the right problem. Before starting or requesting a prescription like Nurtec, take a free, instant, online symptom check to clarify what may be driving your headaches and get personalized guidance on next steps to discuss with your clinician.

Reviewed for medical accuracy: 07/09/2026

answer background

Explanation

What Is Nurtec Used For?

Nurtec (generic name: rimegepant) is an oral medication in the class of calcitonin gene-related peptide (CGRP) receptor antagonists. It is approved by the U.S. Food and Drug Administration (FDA) for two primary uses related to migraine:

  1. Acute Treatment of Migraine
  2. Preventive Treatment of Episodic Migraine

Below is a detailed, plain-language overview of how Nurtec works, when and how it's used, safety considerations, and next steps you can take—including a free online tool to help determine if your symptoms match migraine patterns.


How Nurtec Works

  • Nurtec blocks CGRP receptors.
  • CGRP is a protein involved in transmitting pain signals and widening blood vessels in the brain during a migraine attack.
  • By preventing CGRP from binding to its receptor, Nurtec interrupts the migraine process—relieving pain and associated symptoms.

FDA-Approved Uses

1. Acute Treatment of Migraine

  • Who it's for: Adults experiencing an acute migraine attack, with or without aura.
  • Effectiveness: Provides pain relief and reduces associated symptoms such as nausea, light sensitivity, and sound sensitivity.
  • Onset of action: Many patients notice improvement within 2 hours of a single dose.

2. Preventive Treatment of Episodic Migraine

  • Who it's for: Adults who experience 4 to 14 migraine days per month.
  • Effectiveness: Taken every other day, Nurtec has been shown in clinical trials (Ailani et al., 2021) to reduce the average number of monthly migraine days by about 4 days compared to placebo.
  • Long-term use: Treatment duration depends on individual response; benefits may continue as long as therapy is maintained.

Dosage and Administration

Use Dose Frequency
Acute migraine attack 75 mg orally (tablet dissolves on tongue) Single dose; may repeat once after ≥2 hours if needed (max 150 mg/day)
Preventive therapy (episodic) 75 mg orally Every other day
  • Swallowing is not required; the tablet dissolves on the tongue.
  • Do not exceed the recommended dose.

Safety and Precautions

Common Side Effects

  • Nausea
  • Abdominal pain
  • Fatigue
  • Dry mouth

Serious Warning Signs

If you experience any of the following, seek medical attention immediately:

  • Severe allergic reaction (e.g., hives, difficulty breathing, facial swelling)
  • Chest pain or tightness
  • New or worsening neurological symptoms (e.g., vision changes, weakness)

Liver and Kidney Considerations

  • Mild to Moderate Hepatic Impairment (Child-Pugh A or B): No dose adjustment needed.
  • Severe Hepatic Impairment (Child-Pugh C): Use is not recommended due to lack of safety data and potential for increased drug exposure.
    • Tools such as the MELD score (Kamath & Wiesner, 2001) and Child-Pugh classification can help guide decisions in liver disease.
  • Renal Impairment:
    • Mild to Moderate (eGFR 30–89 mL/min): No adjustment.
    • Severe (eGFR < 30 mL/min) or End-Stage Renal Disease: Use with caution; discuss with your doctor.

Drug Interactions

  • Nurtec is metabolized by the liver enzyme CYP3A4.
  • Avoid strong CYP3A4 inhibitors (e.g., ketoconazole) or inducers (e.g., rifampin) without medical supervision.
  • Always tell your healthcare provider about all prescription and over-the-counter medicines, vitamins, and herbal supplements you take.

Pregnancy and Breastfeeding

  • Pregnant women: Limited data; use only if the potential benefit justifies the potential risk.
  • Breastfeeding: Unknown if Nurtec passes into breast milk; consult your doctor.

Who Should Not Take Nurtec

  • Individuals with a known hypersensitivity to rimegepant or any tablet ingredient.
  • Those with severe liver impairment (Child-Pugh C).
  • Patients taking strong CYP3A4 modifiers without medical guidance.

Monitoring and Follow-Up

  • Keep a migraine diary: Note frequency, severity, and triggers.
  • Assess response: After 2–3 months of preventive therapy, evaluate whether migraine days have meaningfully decreased.
  • Liver function tests: Consider periodically in patients with baseline liver disease.
  • Talk to your doctor if migraines worsen or you develop any concerning symptoms.

Next Steps

If you're experiencing headaches that significantly impact your daily life, use Ubie's free AI-powered migraine symptom checker to quickly assess whether your symptoms align with migraine patterns and receive personalized insights that can guide your conversation with a healthcare provider about whether treatments like Nurtec may be appropriate for you.

Finally, while Nurtec offers an effective option both for treating acute migraine attacks and preventing episodic migraine, speak to a doctor about any serious or life-threatening symptoms you experience. Only a healthcare professional can provide personalized advice, confirm a diagnosis, and ensure safe, effective treatment.

(References)

  • Ailani J, Lipton RB, Hutchinson S, et al. (2021). Rimegepant, an oral CGRP receptor antagonist, for migraine prevention… N Engl J Med, 33771649.

  • Kamath PS, & Wiesner RH. (2001). A model to predict survival in patients with end-stage liver disease. Hepatology, 11157951.

  • European Association for the Study of the Liver. (2018). EASL clinical practice guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology, 29847022.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

smily Shiba-inu looking

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.